Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Analysts

Zura Bio Limited (NASDAQ:ZURA) has received a consensus rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $11.60.

ZURA has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wedbush started coverage on Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 target price on the stock. Wall Street Zen downgraded Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Finally, Chardan Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday, November 14th.

Zura Bio Stock Down 1.3%

Shares of ZURA opened at $6.20 on Monday. The stock has a market capitalization of $403.12 million, a P/E ratio of -9.54 and a beta of 0.21. Zura Bio has a twelve month low of $0.97 and a twelve month high of $6.88. The firm has a fifty day simple moving average of $5.43 and a two-hundred day simple moving average of $3.89.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Zura Bio in the 1st quarter worth approximately $72,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Zura Bio during the second quarter valued at approximately $113,000. Savant Capital LLC grew its stake in Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after purchasing an additional 21,249 shares during the period. Finally, Alberta Investment Management Corp purchased a new stake in Zura Bio in the second quarter worth $140,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.